Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Hangzhou Tigermed Consulting Co Ltd
Cash from Investing Activities
Hangzhou Tigermed Consulting Co Ltd
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Cash from Investing Activities
-¥1.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-27%
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Cash from Investing Activities
-¥7.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Cash from Investing Activities
-¥2.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Cash from Investing Activities
-¥5.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
N/A
|
|
Genscript Biotech Corp
HKEX:1548
|
Cash from Investing Activities
-$561m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Cash from Investing Activities
-¥1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Hangzhou Tigermed Consulting Co Ltd's Cash from Investing Activities?
Cash from Investing Activities
-1.5B
CNY
Based on the financial report for Dec 31, 2023, Hangzhou Tigermed Consulting Co Ltd's Cash from Investing Activities amounts to -1.5B CNY.
What is Hangzhou Tigermed Consulting Co Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-27%
Over the last year, the Cash from Investing Activities growth was 45%. The average annual Cash from Investing Activities growth rates for Hangzhou Tigermed Consulting Co Ltd have been 13% over the past three years , -33% over the past five years , and -27% over the past ten years .